Approval · Notice of Compliance 35508 · 2025
APRETUDE: Notice of Compliance 35508
Issued June 5, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35508
- Date
- June 5, 2025
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety and efficacy information / Update to Patient Medication Information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APRETUDE | Not yet assigned | — |
Medicinal ingredients
- CABOTEGRAVIR 200 MG per ML
- CABOTEGRAVIR SODIUM 30 MG per TAB